Louise Y. Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Louise Y. Cheng has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
Francesca Froldi
Sir Peter MacCallum Department of Oncology, The University of Melbourne
14 shared publicationsCallum Dark
Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
6 shared publications- Phuong-Khanh Nguyen
Sir Peter MacCallum Department of Oncology, The University of Melbourne
6 shared publications Sofya Golenkina
Affiliations Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia
6 shared publicationsQian Dong
Peter MacCallum Cancer Centre, Melbourne, Australia
5 shared publications- Alex P. Gould
The Francis Crick Institute, London, UK
4 shared publications
Latest Publications
- Open Access
- 20 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (21)
Chinmo defines the region-specific oncogenic competence in the Drosophila central nervous system
While genetic mutations can promote hyperplastic growth, they do not always result in oncogenic outcomes. We and others have previously identified the transcription factors Nerfin-1 and Lola as inhibitors of dedifferentiation. Here, we investigate how the oncogenic potential of dedifferentiation varies across different neural lineages in the Drosophila central nervous system. We found that Nerfin-1 inactivation causes tumorigenic phenotypes in the central brain and the ventral nerve cord but not the optic lobes (OLs). In contrast, Lola inactivation leads to tumor overgrowth specifically in the OLs. We identify Chinmo, a temporal transcription factor, and its regulation by ecdysone signaling as key determinants of the oncogenic competence in different regions of the brain, influencing the tumorigenic outcome of dedifferentiation. This study provides a fundamental framework to understand how oncogenic competence arises beyond genetic mutations.
- 20 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (21)
Open AccessChinmo defines the region-specific oncogenic competence in the Drosophila central nervous system
While genetic mutations can promote hyperplastic growth, they do not always result in oncogenic outcomes. We and others have previously identified the transcription factors Nerfin-1 and Lola as inhibitors of dedifferentiation. Here, we investigate how the oncogenic potential of dedifferentiation varies across different neural lineages in the Drosophila central nervous system. We found that Nerfin-1 inactivation causes tumorigenic phenotypes in the central brain and the ventral nerve cord but not the optic lobes (OLs). In contrast, Lola inactivation leads to tumor overgrowth specifically in the OLs. We identify Chinmo, a temporal transcription factor, and its regulation by ecdysone signaling as key determinants of the oncogenic competence in different regions of the brain, influencing the tumorigenic outcome of dedifferentiation. This study provides a fundamental framework to understand how oncogenic competence arises beyond genetic mutations.
- Open Access
- 7 May 2026
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 22 (5) , e1012150
Tumour-driven lipid accumulation in oenocytes reflects systemic lipid alterations
Cancer cachexia is a multifactorial syndrome characterized by systemic metabolic dysfunction, including liver steatosis. In this study, we examined the role of larval oenocytes - hepatocyte-like cells, in a Drosophila model of cancer cachexia. We found that oenocytes in tumour-bearing larvae accumulate lipid droplets in response to tumour-secreted signals, Gbb and ImpL2. This lipid accumulation reflects systemic changes in lipid metabolism, responding to lipid metabolism manipulations in either the fat body or the muscle. Disrupting lipid synthesis/breakdown (via FASN1 and Bmm), storage (via Lsd2), or trafficking (via apolipoproteins) in these tissues significantly modulated lipid droplet accumulation in oenocytes. Moreover, oenocyte-specific knockdown of FASN1 reduced their lipid content and non-autonomously affected lipid droplet size in the fat body, suggesting cross-regulatory interactions between these tissues. Cachectic oenocytes also exhibited altered signaling profiles, characterized by reduced PI3K signalling. Enhancing PI3K signalling through Akt overexpression restored oenocyte size and reduced lipid levels; however, these changes did not significantly improve muscle integrity. Together, our data suggests that dynamic exchange of lipids occur between the fat body, oenocytes and the muscle during cancer cachexia. While the fat body and muscle lipid pools are key regulators of muscle integrity, oenocytes - despite their metabolic responsiveness, do not appear to play an active role in preserving muscle function during cachexia.
- 7 May 2026
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 22 (5) , e1012150
Open AccessTumour-driven lipid accumulation in oenocytes reflects systemic lipid alterations
Cancer cachexia is a multifactorial syndrome characterized by systemic metabolic dysfunction, including liver steatosis. In this study, we examined the role of larval oenocytes - hepatocyte-like cells, in a Drosophila model of cancer cachexia. We found that oenocytes in tumour-bearing larvae accumulate lipid droplets in response to tumour-secreted signals, Gbb and ImpL2. This lipid accumulation reflects systemic changes in lipid metabolism, responding to lipid metabolism manipulations in either the fat body or the muscle. Disrupting lipid synthesis/breakdown (via FASN1 and Bmm), storage (via Lsd2), or trafficking (via apolipoproteins) in these tissues significantly modulated lipid droplet accumulation in oenocytes. Moreover, oenocyte-specific knockdown of FASN1 reduced their lipid content and non-autonomously affected lipid droplet size in the fat body, suggesting cross-regulatory interactions between these tissues. Cachectic oenocytes also exhibited altered signaling profiles, characterized by reduced PI3K signalling. Enhancing PI3K signalling through Akt overexpression restored oenocyte size and reduced lipid levels; however, these changes did not significantly improve muscle integrity. Together, our data suggests that dynamic exchange of lipids occur between the fat body, oenocytes and the muscle during cancer cachexia. While the fat body and muscle lipid pools are key regulators of muscle integrity, oenocytes - despite their metabolic responsiveness, do not appear to play an active role in preserving muscle function during cachexia.
- Open Access
- 18 November 2025
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 23 (11) , e3003496
The blood–brain barrier regulates brain tumor growth through the SLC36 amino acid transporter Pathetic in Drosophila
Tumors adapt their metabolism to sustain increased proliferation, rendering them particularly vulnerable to fluctuations in nutrient availability. However, the role of the tumor microenvironment in modulating sensitivity to nutrient restriction (NR) remains poorly understood. Using a Drosophila brain dedifferentiation neural stem cell (NSC) tumor model induced by Prospero (Pros) inhibition, we show that tumor sensitivity to NR is governed by the blood–brain barrier (BBB) glia. We found that the SLC36 amino acid transporter Pathetic (Path) regulates brain branched-chain amino acids (BCAAs) levels. Under NR, while wild-type buffers against low nutrient levels by upregulating Path, tumor glia down-regulate Path. Furthermore, Path is specifically required by the tumor (but not wildtype) BBB; its downregulation causes reduced cell cycle progression of BBB glial cells and, in turn, restricts NSC tumor growth. Path influences BBB glial cell cycle via the BCAA-mTor-S6K pathway, and its expression is controlled by Ilp6 levels and the Insulin/PI3K pathway. Overexpression of Path is sufficient to counteract the inhibitory effects of NR on tumor growth. These findings suggest that Path levels at the glial niche BBB play a key role in determining tumor sensitivity to NR.
- 18 November 2025
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 23 (11) , e3003496
Open AccessThe blood–brain barrier regulates brain tumor growth through the SLC36 amino acid transporter Pathetic in Drosophila
Tumors adapt their metabolism to sustain increased proliferation, rendering them particularly vulnerable to fluctuations in nutrient availability. However, the role of the tumor microenvironment in modulating sensitivity to nutrient restriction (NR) remains poorly understood. Using a Drosophila brain dedifferentiation neural stem cell (NSC) tumor model induced by Prospero (Pros) inhibition, we show that tumor sensitivity to NR is governed by the blood–brain barrier (BBB) glia. We found that the SLC36 amino acid transporter Pathetic (Path) regulates brain branched-chain amino acids (BCAAs) levels. Under NR, while wild-type buffers against low nutrient levels by upregulating Path, tumor glia down-regulate Path. Furthermore, Path is specifically required by the tumor (but not wildtype) BBB; its downregulation causes reduced cell cycle progression of BBB glial cells and, in turn, restricts NSC tumor growth. Path influences BBB glial cell cycle via the BCAA-mTor-S6K pathway, and its expression is controlled by Ilp6 levels and the Insulin/PI3K pathway. Overexpression of Path is sufficient to counteract the inhibitory effects of NR on tumor growth. These findings suggest that Path levels at the glial niche BBB play a key role in determining tumor sensitivity to NR.
- 1 August 2025
- Published by Springer Nature
- Vol. 1482, 49-60
Nonautonomous Regulation of Tumor Growth
Upon deregulation of growth control, cells and organs lose their ability to maintain size and function. In addition to autonomous mechanisms, nonautonomous regulators play key roles in controlling tumor growth. In this chapter, we will summarize the work, which identified novel communication factors between the tumor and its microenvironment, and the downstream genetic pathways and outputs of these cell-autonomous and nonautonomous interactions during tumor growth.
- 1 August 2025
- Published by Springer Nature
- Vol. 1482, 49-60
Nonautonomous Regulation of Tumor Growth
Upon deregulation of growth control, cells and organs lose their ability to maintain size and function. In addition to autonomous mechanisms, nonautonomous regulators play key roles in controlling tumor growth. In this chapter, we will summarize the work, which identified novel communication factors between the tumor and its microenvironment, and the downstream genetic pathways and outputs of these cell-autonomous and nonautonomous interactions during tumor growth.
- Open Access
Tumour-driven lipid accumulation in oenocytes reflects systemic lipid alterations
Cancer cachexia is a multifactorial syndrome characterized by systemic metabolic dysfunction, including liver steatosis. In this study, we examined the role of larval oenocytes - hepatocyte-like cells, in a Drosophila model of cancer cachexia. We found that oenocytes in tumour-bearing larvae accumulate lipid droplets in response to tumour-secreted signals, Gbb and ImpL2. This lipid accumulation reflects systemic changes in lipid metabolism, responding to lipid metabolism manipulations in either the fat body or the muscle. Disrupting lipid synthesis (via FASN1 and DGAT1), storage (via Lsd2), or trafficking (via apolipoproteins) in these tissues significantly modulated lipid droplet accumulation in oenocytes. Moreover, oenocyte-specific knockdown of FASN1 reduced their lipid content and non-autonomously affected lipid droplet size in the fat body, suggesting cross-regulatory interactions between these tissues. Cachectic oenocytes also exhibited altered signaling profiles, characterized by reduced PI3K and elevated Wnt and Ecdysone activity. Enhancing PI3K signaling through Akt overexpression restored oenocyte size and reduced lipid levels; however, these changes did not significantly improve muscle integrity. Together, our data suggests that dynamic exchange of lipids occur between the fat body, oenocytes and the muscle during cancer cachexia. While the fat body and muscle lipid pools are key regulators of muscle integrity, oenocytes - despite their metabolic responsiveness, do not appear to play an active role in preserving muscle function during cachexia.
Open AccessTumour-driven lipid accumulation in oenocytes reflects systemic lipid alterations
Cancer cachexia is a multifactorial syndrome characterized by systemic metabolic dysfunction, including liver steatosis. In this study, we examined the role of larval oenocytes - hepatocyte-like cells, in a Drosophila model of cancer cachexia. We found that oenocytes in tumour-bearing larvae accumulate lipid droplets in response to tumour-secreted signals, Gbb and ImpL2. This lipid accumulation reflects systemic changes in lipid metabolism, responding to lipid metabolism manipulations in either the fat body or the muscle. Disrupting lipid synthesis (via FASN1 and DGAT1), storage (via Lsd2), or trafficking (via apolipoproteins) in these tissues significantly modulated lipid droplet accumulation in oenocytes. Moreover, oenocyte-specific knockdown of FASN1 reduced their lipid content and non-autonomously affected lipid droplet size in the fat body, suggesting cross-regulatory interactions between these tissues. Cachectic oenocytes also exhibited altered signaling profiles, characterized by reduced PI3K and elevated Wnt and Ecdysone activity. Enhancing PI3K signaling through Akt overexpression restored oenocyte size and reduced lipid levels; however, these changes did not significantly improve muscle integrity. Together, our data suggests that dynamic exchange of lipids occur between the fat body, oenocytes and the muscle during cancer cachexia. While the fat body and muscle lipid pools are key regulators of muscle integrity, oenocytes - despite their metabolic responsiveness, do not appear to play an active role in preserving muscle function during cachexia.
- 13 June 2025
- Published by Elsevier in Current Opinion in Cell Biology
- Vol. 95, 102560
From brain-sparing to prioritised tumour growth: Insights into tumour-host interactions
- 13 June 2025
- Published by Elsevier in Current Opinion in Cell Biology
- Vol. 95, 102560
From brain-sparing to prioritised tumour growth: Insights into tumour-host interactions
- Open Access
Chinmo defines the region-specific oncogenic competence in the Drosophila central nervous system
While genetic mutations can promote hyperplastic growth, they do not always result in oncogenic outcomes. We and others have previously identified the transcription factors Nerfin-1 and Lola as inhibitors of dedifferentiation. Here, we investigate how the oncogenic potential of dedifferentiation varies across different neural lineages in the Drosophila central nervous system (CNS). We found that Nerfin-1 inactivation causes tumorigenic phenotypes in the central brain (CB) and the ventral nerve cord (VNC) but not the optic lobes (OLs). In contrast, Lola inactivation leads to tumour overgrowth specifically in the OLs. We identify Chinmo, a temporal transcription factor, and its regulation by ecdysone signalling as key determinants of the oncogenic competence in different regions of the brain, influencing the tumorigenic outcome of dedifferentiation. This work provides a fundamental framework to understand how oncogenic competence arises beyond genetic mutations. Significance statement: In the CNS, the same tumorigenic mutation has been shown cause differential oncogenic outcomes in different regions of the brain. The mechanism underlying this phenomenon remains largely unknown. We have previously demonstrated that malignant brain tumours can be induced via neuronal dedifferentiation in the Drosophila CNS. Here, we demonstrate that dedifferentiated neural stem cells drive tumorigenesis in a region-specific manner, accounted for by region-specific expression and regulation of temporal factors by cell-intrinsic and hormonal signals. Together, this work extends our understandings of how brain regionalisation can be a constraint to oncogenesis.
Open AccessChinmo defines the region-specific oncogenic competence in the Drosophila central nervous system
While genetic mutations can promote hyperplastic growth, they do not always result in oncogenic outcomes. We and others have previously identified the transcription factors Nerfin-1 and Lola as inhibitors of dedifferentiation. Here, we investigate how the oncogenic potential of dedifferentiation varies across different neural lineages in the Drosophila central nervous system (CNS). We found that Nerfin-1 inactivation causes tumorigenic phenotypes in the central brain (CB) and the ventral nerve cord (VNC) but not the optic lobes (OLs). In contrast, Lola inactivation leads to tumour overgrowth specifically in the OLs. We identify Chinmo, a temporal transcription factor, and its regulation by ecdysone signalling as key determinants of the oncogenic competence in different regions of the brain, influencing the tumorigenic outcome of dedifferentiation. This work provides a fundamental framework to understand how oncogenic competence arises beyond genetic mutations. Significance statement: In the CNS, the same tumorigenic mutation has been shown cause differential oncogenic outcomes in different regions of the brain. The mechanism underlying this phenomenon remains largely unknown. We have previously demonstrated that malignant brain tumours can be induced via neuronal dedifferentiation in the Drosophila CNS. Here, we demonstrate that dedifferentiated neural stem cells drive tumorigenesis in a region-specific manner, accounted for by region-specific expression and regulation of temporal factors by cell-intrinsic and hormonal signals. Together, this work extends our understandings of how brain regionalisation can be a constraint to oncogenesis.
- Open Access
The blood-brain barrier regulates brain tumour growth specifically via the SLC36 amino acid transporter Pathetic in Drosophila
Tumours adapt their metabolism to sustain increased proliferation, rendering them particularly vulnerable to fluctuations in nutrient availability. However, the role of the tumour microenvironment in modulating sensitivity to nutrient restriction (NR) remains poorly understood. Using a Drosophila brain dedifferentiation neural stem cell (NSC) tumour model induced by Prospero (Pros) inhibition, we show that tumour sensitivity to NR is governed by the perineural glial (PG) cells of the blood-brain barrier (BBB), a major component of the glial niche surrounding the tumour. We identify the SLC36 amino acid transporter Pathetic (Path) as a crucial regulator of nutrient sensitivity. Under NR, while wildtype buffers against low nutrient levels by upregulating Path, tumour glia downregulate Path. Furthermore, Path is specifically required by the tumour (but not wildtype) PG; its downregulation causes reduced proliferation of PG cells and, in turn, restricts NSC tumour growth. Path influences PG proliferation via the mTor-S6K pathway, and its expression is controlled by Ilp6 levels and the Insulin/PI3K pathway. Overexpression of Path is sufficient to counteract the inhibitory effects of NR on tumour growth. These findings suggest that Path levels at the BBB play a key role in determining tumour sensitivity to NR.
Open AccessThe blood-brain barrier regulates brain tumour growth specifically via the SLC36 amino acid transporter Pathetic in Drosophila
Tumours adapt their metabolism to sustain increased proliferation, rendering them particularly vulnerable to fluctuations in nutrient availability. However, the role of the tumour microenvironment in modulating sensitivity to nutrient restriction (NR) remains poorly understood. Using a Drosophila brain dedifferentiation neural stem cell (NSC) tumour model induced by Prospero (Pros) inhibition, we show that tumour sensitivity to NR is governed by the perineural glial (PG) cells of the blood-brain barrier (BBB), a major component of the glial niche surrounding the tumour. We identify the SLC36 amino acid transporter Pathetic (Path) as a crucial regulator of nutrient sensitivity. Under NR, while wildtype buffers against low nutrient levels by upregulating Path, tumour glia downregulate Path. Furthermore, Path is specifically required by the tumour (but not wildtype) PG; its downregulation causes reduced proliferation of PG cells and, in turn, restricts NSC tumour growth. Path influences PG proliferation via the mTor-S6K pathway, and its expression is controlled by Ilp6 levels and the Insulin/PI3K pathway. Overexpression of Path is sufficient to counteract the inhibitory effects of NR on tumour growth. These findings suggest that Path levels at the BBB play a key role in determining tumour sensitivity to NR.
- Open Access
Tumour-derived gliogenesis sustains dedifferentiation-dependent tumour growth in the Drosophila CNS
Fate-restricted cells can acquire stem cell-like properties through dedifferentiation, enabling them to gain the plasticity required for differentiation into multiple lineages. Tumour plasticity is prominently observed in brain cancers, where transient cell state changes are linked to resistance to conventional therapies. In this study, we demonstrate that a sub-population of dedifferentiated tumour neural stem cells (NSCs) in Drosophila , induced by the knockdown of prospero ( pros ), can generate its own glial niche. Temporal patterning, known to influence oncogenic competence and tumour malignancy, plays a key role in this process. Specifically, we show that de novo gliogenesis occurs in the more differentiated Syncrip+ (Syp + ) NSC population. Modulating Syp levels alters the size of the glial niche, subsequently affecting tumour size. Furthermore, the tumour-associated glial niche expands through cell division and fails to cease proliferation on time due to dysregulated ecdysone signalling, contributing to niche expansion. Our findings reveal that tumours arising via dedifferentiation establish their own supportive glial microenvironment, which sustains tumour growth.
Open AccessTumour-derived gliogenesis sustains dedifferentiation-dependent tumour growth in the Drosophila CNS
Fate-restricted cells can acquire stem cell-like properties through dedifferentiation, enabling them to gain the plasticity required for differentiation into multiple lineages. Tumour plasticity is prominently observed in brain cancers, where transient cell state changes are linked to resistance to conventional therapies. In this study, we demonstrate that a sub-population of dedifferentiated tumour neural stem cells (NSCs) in Drosophila , induced by the knockdown of prospero ( pros ), can generate its own glial niche. Temporal patterning, known to influence oncogenic competence and tumour malignancy, plays a key role in this process. Specifically, we show that de novo gliogenesis occurs in the more differentiated Syncrip+ (Syp + ) NSC population. Modulating Syp levels alters the size of the glial niche, subsequently affecting tumour size. Furthermore, the tumour-associated glial niche expands through cell division and fails to cease proliferation on time due to dysregulated ecdysone signalling, contributing to niche expansion. Our findings reveal that tumours arising via dedifferentiation establish their own supportive glial microenvironment, which sustains tumour growth.
- Open Access
- 21 June 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Drosophila medulla neuroblast termination via apoptosis, differentiation, and gliogenic switch is scheduled by the depletion of the neuroepithelial stem cell pool
The brain is consisted of diverse neurons arising from a limited number of neural stem cells. Drosophila neural stem cells called neuroblasts (NBs) produces specific neural lineages of various lineage sizes depending on their location in the brain. In the Drosophila visual processing centre - the optic lobes (OLs), medulla NBs derived from the neuroepithelium (NE) give rise to neurons and glia cells of the medulla cortex. The timing and the mechanisms responsible for the cessation of medulla NBs are so far not known. In this study, we show that the termination of medulla NBs during early pupal development is determined by the exhaustion of the NE stem cell pool. Hence, altering NE-NB transition during larval neurogenesis disrupts the timely termination of medulla NBs. Medulla NBs terminate neurogenesis via a combination of apoptosis, terminal symmetric division via Prospero, and a switch to gliogenesis via Glial Cell Missing (Gcm); however, these processes occur independently of each other. We also show that temporal progression of the medulla NBs is mostly not required for their termination. As the Drosophila OL shares a similar mode of division with mammalian neurogenesis, understanding when and how these progenitors cease proliferation during development can have important implications for mammalian brain size determination and regulation of its overall function.
- 21 June 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessDrosophila medulla neuroblast termination via apoptosis, differentiation, and gliogenic switch is scheduled by the depletion of the neuroepithelial stem cell pool
The brain is consisted of diverse neurons arising from a limited number of neural stem cells. Drosophila neural stem cells called neuroblasts (NBs) produces specific neural lineages of various lineage sizes depending on their location in the brain. In the Drosophila visual processing centre - the optic lobes (OLs), medulla NBs derived from the neuroepithelium (NE) give rise to neurons and glia cells of the medulla cortex. The timing and the mechanisms responsible for the cessation of medulla NBs are so far not known. In this study, we show that the termination of medulla NBs during early pupal development is determined by the exhaustion of the NE stem cell pool. Hence, altering NE-NB transition during larval neurogenesis disrupts the timely termination of medulla NBs. Medulla NBs terminate neurogenesis via a combination of apoptosis, terminal symmetric division via Prospero, and a switch to gliogenesis via Glial Cell Missing (Gcm); however, these processes occur independently of each other. We also show that temporal progression of the medulla NBs is mostly not required for their termination. As the Drosophila OL shares a similar mode of division with mammalian neurogenesis, understanding when and how these progenitors cease proliferation during development can have important implications for mammalian brain size determination and regulation of its overall function.